An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Kevin H. Hall, PharmD, BCOP
Advertisement
Articles by Kevin H. Hall, PharmD, BCOP
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Considering Venlafaxine as Distress Treatment in Breast Cancer
5